about
Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrowCongenital cytopenias and bone marrow failure syndromes.Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease.Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell miceHigh-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy.Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression.The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiationPharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease.Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons.RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model
P50
Q33381047-59B8F656-0EB9-47A5-9DFF-57E0094B8935Q33382902-5F3A7FAB-C646-4318-8547-8A96136D5954Q33922182-B44E8FE6-D422-43B9-9CEF-6516C15824A2Q34170303-325AFCAF-424A-4035-BF8B-A0DC3D7FF997Q34634722-D2D30050-802C-4940-97C7-56FDCFD54DB7Q35859235-00BCE69C-ECAB-4C57-9080-74A24B4DDB16Q35973549-EB4DB571-38BA-4A9C-859C-3DE8FF810086Q37011792-73EBC175-CE20-4053-8E07-529BEB6E906CQ39064354-B81ED162-D2B1-42B8-BD3A-DD73F25FB3E7Q39993695-3A03B091-ED45-4D46-AE5B-7DD4D6973223Q41032514-1B1C21AA-916E-4AAC-B795-8C33D1A2C2EFQ41897344-85CB4596-68AA-4C7B-A364-7930B5D93D70Q46412324-127C6653-3BA1-4A68-8100-D8C970A008E1Q48023276-6B0AC894-76F3-47DF-9C94-531B7FBDF72EQ61697710-47C495D5-25E9-47CF-8D14-957D1015074C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angela E Rivers
@ast
Angela E Rivers
@en
Angela E Rivers
@es
Angela E Rivers
@nl
Angela E Rivers
@sl
type
label
Angela E Rivers
@ast
Angela E Rivers
@en
Angela E Rivers
@es
Angela E Rivers
@nl
Angela E Rivers
@sl
prefLabel
Angela E Rivers
@ast
Angela E Rivers
@en
Angela E Rivers
@es
Angela E Rivers
@nl
Angela E Rivers
@sl
P106
P21
P31
P496
0000-0002-7989-0522